Biomarkers in localized prostate cancer

被引：41

作者：

Ferro, Matteo ^{[1
]}

Buonerba, Carlo ^{[2
]}

Terracciano, Daniela ^{[3
]}

Lucarelli, Giuseppe ^{[4
]}

Cosimato, Vincenzo ^{[3
]}

Bottero, Danilo ^{[1
]}

Deliu, Victor M. ^{[1
]}

Ditonno, Pasquale ^{[4
]}

Perdona, Sisto ^{[5
]}

Autorino, Riccardo ^{[6
]}

Coman, Ioman ^{[7
]}

De Placido, Sabino ^{[2
]}

Di Lorenzo, Giuseppe ^{[2
]}

De Cobelli, Ottavio ^{[1
,7
]}

机构：

[1] European Inst Oncol, Div Oncol, Milan, Italy

[2] Univ Naples Federico II, Dept Clin Med & Surg, Med Oncol, Naples, Italy

[3] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy

[4] Univ Bari, Dept Emergency & Organ Transplantat Urol, Androl & Kidney Transplantat Unit, Bari, Italy

[5] Natl Canc Inst, Dept Urol, Naples, Italy

[6] Univ Hosp Case Med Ctr, Inst Urol, Cleveland, OH 44106 USA

[7] Univ Med & Pharm, Dept Urol Iuliu Hatieganu, Cluj Napoca 400012, Romania

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 03期

关键词：

biomarkers; prostate cancer; HEALTH INDEX PHI; ANTIGEN VELOCITY; ACTIVE SURVEILLANCE; KALLIKREIN MARKERS; SERUM SARCOSINE; BIOPSY RECLASSIFICATION; RADICAL PROSTATECTOMY; PROGNOSTIC VALUE; PRECURSOR FORM; RISK;

D O I：

10.2217/fon.15.318

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biomarkers can improve prostate cancer diagnosis and treatment. Accuracy of prostate-specific antigen (PSA) for early diagnosis of prostate cancer is not satisfactory, as it is an organ-but not cancer-specific biomarker, and it can be improved by using models that incorporate PSA along with other test results, such as prostate cancer antigen 3, the molecular forms of PSA (proPSA, benign PSA and intact PSA), as well as kallikreins. Recent reports suggest that new tools may be provided by metabolomic studies as shown by preliminary data on sarcosine. Additional molecular biomarkers have been identified by the use of genomics, proteomics and metabolomics. We review the most relevant biomarkers for early diagnosis and management of localized prostate cancer.

引用

页码：399 / 411

页数：13

共 50 条

[11] Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer
Costa-Pinheiro, Pedro
Patel, Hiten R. H.
Henrique, Rui
Jeronimo, Carmen
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1349 - 1358
[12] Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer
Brastianos, Harry C.
Murgic, Jure
Salcedo, Adriana
Chua, Melvin L. K.
Meng, Alice
Fraser, Michael
Brundage, Michael
Fleshner, Neil E.
van der Kwast, Theodorus
Bristow, Robert G.
Boutros, Paul C.
Berlin, Alejandro
[J]. EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (03): : 362 - 365
[13] Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
Moschini, Marco
Spahn, Martin
Mattei, Agostino
Cheville, John
Karnes, R. Jeffrey
[J]. BMC MEDICINE, 2016, 14
[14] Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
Marco Moschini
Martin Spahn
Agostino Mattei
John Cheville
R. Jeffrey Karnes
[J]. BMC Medicine, 14
[15] Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer
Ingrosso, Gianluca
Ali, Emanuele
Marani, Simona
Saldi, Simonetta
Bellavita, Rita
Aristei, Cynthia
[J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (01):
[16] Localized prostate cancer
Walsh, Patrick C.
DeWeese, Theodore L.
Eisenberger, Mario A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26): : 2696 - 2705
[17] Localized prostate cancer
Sailer, V. W.
Perner, S.
Wild, P.
Koellermann, J.
[J]. PATHOLOGE, 2021, 42 (06): : 603 - 616
[18] Localized prostate cancer
Krongrad, A
[J]. UROLOGIC CLINICS OF NORTH AMERICA, 2003, 30 (02) : XV - XV
[19] Localized cancer of the prostate
Mottet, N
[J]. EUROCANCER 98, 1998, : 335 - 336
[20] Localized prostate cancer
Kapoor, Anil
Hotte, Sebastien J.
[J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (7-8): : S138 - S139

← 1 2 3 4 5 →